Previous 10 | Next 10 |
home / stock / orxoy / orxoy news
Orexo publishes 2021 Annual Report PR Newswire UPPSALA, Sweden , March 31, 2022 /PRNewswire/ -- Orexo's Annual Report for the 2021 has been published. The Annual Report can be downloaded on the company's website, www.orexo.com , and a PDF is...
Orexo (OTCQX:ORXOY) has appointed Fredrik Järrsten as new Chief Financial Officer and a member of the management team, starting at latest in early September, 2022 to succeed Joseph DeFeo. Fredrik Järrsten, most recently served as CFO for Oasmia Pharmaceutical AB and Karolinska Devel...
Orexo appoints Fredrik Järrsten as new CFO PR Newswire UPPSALA, Sweden , March 11, 2022 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), announces today that the company has appointed Fredrik Järrsten as new Chief Financial Officer (CFO) a...
Orexo (OTCQX:ORXOY) announced improved market access for its drug Zubsolv (buprenorphine and naloxone) sublingual tablet (CIII) for opioid dependence, following the new MAT formulary effective March 22, 2022 by the New York Department of Health. The company said Zubsolv will be avai...
Orexo's lead product ZUBSOLV® added to NY State Medicaid MAT Preferred Drug List - ZUBSOLV® will be available to all patients with Medicaid insurance in NY state effective March 22, 2022 - ZUBSOLV® market access improves in the public segment to 48 percent unr...
Orexo Q4 2021, incl. Full Year Report PR Newswire UPPSALA, Sweden , Jan. 27, 2022 /PRNewswire/ -- Ready to capitalize on a strong foundation Q4 2021 highlights Total net revenues of SEK 144.0 m (159.2) Net earnings of SEK -66....
Orexo develops a nasal adrenaline medication based on the novel amorphOXTM platform The development pipeline is broadening with a nasal adrenaline medication, targeting a global and growing unmet medical need If approved, the medication would provide important benefits to pa...
Orexo provides information about its new proprietary drug delivery platform - amorphOXTM PR Newswire - amorphOX TM is a novel and inventive drug delivery platform that can be used to develop highly differentiated products with various active ingredients and administr...
Orexo announces positive results from pivotal trial for its leading pharmaceutical pipeline asset OX124 - The pivotal trial OX124-002 meets the primary endpoints in the 4-period crossover, comparative bioavailability study in healthy volunteers - OX124 showed a significantly...
Orexo Q3 2021 Interim Report Steady progression on our journey to build a broader and stronger Orexo PR Newswire UPPSALA, Sweden , Nov. 3, 2021 /PRNewswire/ -- Q3 2021 highlights Total net revenues of SEK 145.9 m (150.3) Net earnings of ...
News, Short Squeeze, Breakout and More Instantly...
Orexo: invitation to presentation of the Q2 2024 Interim Report PR Newswire UPPSALA, Sweden , July 8, 2024 /PRNewswire/ -- As previously communicated Orexo will announce the Interim Report for the second quarter of 2024 on July 17 at 8 am CET . The same ...
NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum held June 20 th are now available for online viewing. REGISTER NOW AT : ...
NEW YORK, June 18, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Virtual Investor Forum to be held on June 20 th , 2024. This event is co-sponsored by Zack’s Small Cap Research. ...